NCT01852266View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV cps2 Vaccine

10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).

BIOLOGICAL

Placebo Vaccine

Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).

Trial Locations (2)

20708

Johns Hopkins University, Center for Immunization Research South, Laurel

21505

Johns Hopkins University, Center for Immunization Research (CIR), Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01852266 - Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter